Article Text

Download PDFPDF
Review: paroxetine and placebo do not differ for treatment discontinuation in major depression

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

C Barbui

Dr C Barbui, University of Verona, Verona, Italy;


In participants with major depression, what is the effectiveness and acceptability of paroxetine?


Included studies compared any flexible- or fixed-dose (⩾20 mg/d) regimen of any pharmaceutical form of paroxetine with placebo in participants ⩾18 years of age with major depression. Outcomes included treatment discontinuation, depression, <50% improvement in symptoms, adverse events, and suicidal tendencies.


Medline; EMBASE/Excerpta Medica; Cochrane Collaboration Depression, Anxiety, and Neurosis Controlled Trials Register; Cochrane Central Register of Controlled Trials; and Glaxo-SmithKline Clinical Trial Register (all to December 2006) were searched for published and unpublished randomised placebo controlled trials (RCTs). 29 published RCTs and 11 unpublished RCTs (n = 6391) were included in …

View Full Text


  • Source of funding: Japanese Ministry of Education, Science and Technology and Japanese Ministry of Health Labour and Welfare.